Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
KRM Ayurveda IPO
Price Band
₹128.0–135.0
Issue Size
₹77.49 Cr
Lot Size
1,000 shares
Min Investment
₹270,000
2 LOTS MIN
GMP
+₹22.5 (16.67%)
Issue Price
₹135.0
KRM Ayurveda IPO AI Summary
- KRM Ayurveda IPO is listed on NSE SME in the Pharmaceuticals sector.
- Price band: ₹128.0–₹135.0 per share, lot size 1,000 shares (min. investment ₹270,000, 2 lots minimum).
- Subscription window: 21 Jan–23 Jan 2026, listing on 29 Jan 2026.
- Current GMP is +₹22.5 (16.67%), an estimated listing price of ₹158 — unofficial and can change daily.
KRM Ayurveda Ltd. is set to enter the market with an IPO priced at ₹135.0 per share, aiming to raise ₹77.49 Cr. The company operates in the Ayurvedic healthcare sector with a network of hospitals and clinics, and it has a positive outlook based on its growth strategies and established brand presence.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Subscription data unavailable
KRM Ayurveda IPO Grey Market Premium (GMP) Today
GMP
+₹22.5
GMP %
+16.67%
Est. Listing
₹157.5
Updated: 14 Jul 2026 15:52
About the Company
Incorporated on 3 September 2019, KRM Ayurveda Ltd. is operating a network of hospitals and clinics across multiple cities in India as well as marked its presence in abroad through telemedicines consulting and sales. They manufacture Ayurvedic products, herbal and botanical remedies, medicines, supplements and possibly skin care / wellness related items. Presently, the company runs 6 (Six) Hospitals and 5 (Five) Clinics at different locations in the country. Hospitals and Clinics are equipped with the following infrastructure & facilities: Beds, including general wards and premium rooms. Panchakarma treatment units. Herbal pharmacy and medicine preparation unit. Ayurvedic diet kitchen Consultation chambers for Vaidyas (Ayurvedic physicians). In-house yoga and meditation hall. Services: In-Patient & Out-Patient Care: Treatment for chronic diseases, lifestyle disorders, and post-operative rehabilitation. Panchakarma Therapies: Detoxification and rejuvenation programs. Specialized Clinics: Orthopedic care, skin and hair care, women’s wellness, geriatric care. Wellness Packages: Stress management, weight management, preventive health plans. Medicinal Sales: Dispensary of in-house and certified Ayurvedic medicines. Diet & Lifestyle Counseling: Personalized nutrition and yoga consultation As on December 31, 2025, the company have total of 443 employees operating under various departments. Competitive Strengths: Skilled Ayurvedic physicians and certified therapists ensuring treatment quality. Centralized GMP-certified production of Ayurvedic medicines ensuring purity and efficacy. Trusted brand with loyal customer base and repeat clientele.
Company Financials (₹ Cr)
As of 2025-03-31
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 78.12 | 66.79 | 43.91 | 39.48 |
| Total Income | 48.65 | 76.95 | 67.57 | 89.38 |
| Profit After Tax | 8.14 | 12.10 | 3.41 | 7.60 |
| EBITDA | 12.83 | 19.11 | 7.34 | 11.03 |
| NET Worth | 36.13 | 23.88 | 11.78 | 8.37 |
| Reserves and Surplus | 20.61 | 23.73 | 11.63 | 8.22 |
| Total Borrowing | 25.07 | 31.20 | 23.18 | 19.87 |
Key Ratios
EPS
₹7.79
NAV
₹1602.40
ROE
67.86%
ROCE
43.33%
RoNW
67.86%
P/B Value
0.08
P/E Ratio
17.32
Market Cap
₹287.02 Cr
PAT Margin
15.80%
Debt/Equity
1.31
Promoters
Puneet Dhawan and Tanya Dhawan
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Capital Expenditure for Construction and Development of Telemedicine Operational Facilities 13.67 2 Purchase of CRM Software and Hardware Infrastructure 1.42 3 Human Resources 5.44 4 Repayment/Prepayment of loan 12.50 5 Working Capital Requirement 22.90 6 General Corporate Purposes 10.00 7 Issue Expenses 11.57 Total 77.49
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹89.38 Cr in the year ending 31 Mar 2023, decreasing to ₹76.95 Cr by 31 Mar 2025. However, the most recent figure of ₹48.65 Cr as of 30 Sep 2025 is not directly comparable as it represents a 9-month period.
Profit Trend
Profit After Tax was ₹7.60 Cr for the year ending 31 Mar 2023, rising to ₹12.10 Cr by 31 Mar 2025. The most recent figure of ₹8.14 Cr as of 30 Sep 2025 is also a 9-month figure and not directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the premium at which an IPO is expected to list compared to its issue price. A positive GMP suggests strong demand, while a negative GMP can indicate weaker interest. Investors often look at the GMP to gauge potential listing-day performance.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and risk tolerance. It's important to consider the company's fundamentals, market position, and growth potential.
Who May Want to Wait
Investors who are risk-averse or prefer stable, established companies may want to avoid this IPO. Those who are not familiar with the pharmaceutical or Ayurvedic sectors might also consider other investment options.
IPO Timeline, Explained
The IPO opens for subscription on 21 January 2026 and closes on 23 January 2026. Allotment of shares will be done on 27 January 2026, with the listing expected on 29 January 2026.
Listing Gains — The Risk
Listing-day gains can be unpredictable and depend on market conditions, investor sentiment, and the overall demand for the stock. While some IPOs experience significant gains on their first day of trading, others may not perform as expected. Investors should be prepared for the possibility of volatility.
This evaluation is generated from KRM Ayurveda's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is KRM Ayurveda IPO GMP today?
KRM Ayurveda IPO GMP today is +₹22.5 (16.67%), indicating an estimated listing price of ₹158. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of KRM Ayurveda IPO?
The price band of KRM Ayurveda IPO is ₹128.0–₹135.0 per share.
When does KRM Ayurveda IPO open and close?
KRM Ayurveda IPO opens on 21 January 2026 and closes on 23 January 2026.
When does KRM Ayurveda IPO list on the stock exchange?
KRM Ayurveda IPO listed on 29 January 2026 at ₹157.5.
What is the lot size for KRM Ayurveda IPO?
The lot size for KRM Ayurveda IPO is 1000 shares, requiring a minimum investment of ₹270,000 (2 lots).
What is the lot size for this IPO?
The lot size for KRM Ayurveda's IPO is 1000 shares.
What is the minimum investment required?
The minimum investment required is ₹2,70,000.
What is the price band for the IPO?
The price band for the IPO is between ₹128.0 and ₹135.0.
When is the listing date?
The listing date is scheduled for 29 January 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium at which the stock may list compared to its issue price.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
21 Jan 2026
Close
23 Jan 2026
Allotment
27 Jan 2026
Listing
29 Jan 2026
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for KRM Ayurveda?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.